Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Acquired by Rehmann Capital Advisory Group

Rehmann Capital Advisory Group boosted its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 112.9% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,452 shares of the biopharmaceutical company's stock after acquiring an additional 770 shares during the quarter. Rehmann Capital Advisory Group's holdings in Regeneron Pharmaceuticals were worth $921,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in REGN. Capital International Investors lifted its holdings in shares of Regeneron Pharmaceuticals by 41.6% in the 4th quarter. Capital International Investors now owns 4,736,929 shares of the biopharmaceutical company's stock worth $3,373,859,000 after buying an additional 1,390,534 shares during the period. Norges Bank purchased a new stake in shares of Regeneron Pharmaceuticals in the 4th quarter worth $802,036,000. GAMMA Investing LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 89,825.0% in the 1st quarter. GAMMA Investing LLC now owns 815,620 shares of the biopharmaceutical company's stock worth $517,291,000 after buying an additional 814,713 shares during the period. Price T Rowe Associates Inc. MD lifted its holdings in shares of Regeneron Pharmaceuticals by 63.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 2,085,447 shares of the biopharmaceutical company's stock worth $1,485,527,000 after buying an additional 810,144 shares during the period. Finally, Loomis Sayles & Co. L P lifted its holdings in shares of Regeneron Pharmaceuticals by 33.4% in the 4th quarter. Loomis Sayles & Co. L P now owns 1,575,349 shares of the biopharmaceutical company's stock worth $1,122,168,000 after buying an additional 393,997 shares during the period. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several brokerages have weighed in on REGN. Royal Bank Of Canada cut Regeneron Pharmaceuticals from a "moderate buy" rating to a "hold" rating and set a $662.00 target price for the company. in a report on Friday, May 30th. Morgan Stanley reduced their price target on Regeneron Pharmaceuticals from $755.00 to $754.00 and set an "overweight" rating for the company in a research report on Thursday. The Goldman Sachs Group reduced their price target on Regeneron Pharmaceuticals from $917.00 to $804.00 and set a "buy" rating for the company in a research report on Wednesday, April 30th. Bank of America reduced their price target on Regeneron Pharmaceuticals from $575.00 to $547.00 and set an "underperform" rating for the company in a research report on Thursday, April 17th. Finally, Guggenheim reissued a "buy" rating on shares of Regeneron Pharmaceuticals in a research report on Friday, May 30th. One research analyst has rated the stock with a sell rating, seven have given a hold rating, sixteen have given a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $822.54.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN traded up $5.23 during mid-day trading on Friday, reaching $564.99. The company had a trading volume of 371,000 shares, compared to its average volume of 912,017. Regeneron Pharmaceuticals, Inc. has a 52-week low of $476.49 and a 52-week high of $1,211.20. The company has a quick ratio of 4.03, a current ratio of 4.93 and a debt-to-equity ratio of 0.09. The stock has a market capitalization of $61.00 billion, a P/E ratio of 14.34, a PEG ratio of 2.06 and a beta of 0.33. The stock has a 50 day moving average of $545.98 and a two-hundred day moving average of $621.52.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 EPS for the quarter, missing analysts' consensus estimates of $8.83 by ($0.61). Regeneron Pharmaceuticals had a return on equity of 15.27% and a net margin of 31.94%. The company had revenue of $3.03 billion during the quarter, compared to analysts' expectations of $3.40 billion. During the same quarter in the previous year, the company earned $9.55 EPS. The firm's quarterly revenue was down 3.7% compared to the same quarter last year. On average, analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, June 6th. Shareholders of record on Tuesday, May 20th were given a dividend of $0.88 per share. The ex-dividend date of this dividend was Tuesday, May 20th. This represents a $3.52 dividend on an annualized basis and a yield of 0.62%. Regeneron Pharmaceuticals's dividend payout ratio is currently 8.96%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.